Emil Egecioglu,Karolina P Skibicka,Caroline Hansson et al.
Emil Egecioglu et al.
Here we review the emerging neurobiological understanding of the role of the brain's reward system in the regulation of body weight in health and in disease. Common obesity is characterized by the over-consumption of palatable/rewarding foo...
Chung Thong Lim,Blerina Kola,Márta Korbonits
Chung Thong Lim
Ghrelin is a brain-gut peptide that was discovered through reverse pharmacology and was first isolated from extracts of porcine stomach. Ghrelin binds to growth hormone secretagogue receptor (GHS-R) and is acylated on its serine 3 residue b...
Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle [0.03%]
内源大麻素系统在能量稳态的外周效应：脂肪组织、肝脏和骨骼肌
Cristoforo Silvestri,Alessia Ligresti,Vincenzo Di Marzo
Cristoforo Silvestri
The endocannabinoid system (ECS) is composed of lipid signalling ligands, their G-protein coupled receptors and the enzymes involved in ligand generation and metabolism. Increasingly, the ECS is emerging as a critical agent of energy metabo...
Obesity-associated insulin resistance in skeletal muscle: role of lipid accumulation and physical inactivity [0.03%]
肥胖相关骨骼肌胰岛素抵抗：脂质蓄积和身体活动不足的作用
Kristin Eckardt,Annika Taube,Juergen Eckel
Kristin Eckardt
An alarming increase in the prevalence of obesity, type 2 diabetes mellitus, and associated diseases can be observed world-wide during the past 20 years. In obesity, profound alterations in the secretion profile of adipokines and inflammato...
Is the GLP-1 system a viable therapeutic target for weight reduction? [0.03%]
GLP-1系统在体重降低治疗中的潜力与局限性
Jenny Tong,Darleen A Sandoval
Jenny Tong
Incretin hormones are intestinally derived peptides that are known to augment glucose-stimulated insulin secretion and suppress glucagon levels. Incretin mimetics are attractive adjunctive therapy for type 2 diabetes due to its efficacy on ...
Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism [0.03%]
关于内分泌学会实践指南的述评：在原发性醛固酮增多症筛查中调整抗高血压药物的后果
Evelyn Fischer,Felix Beuschlein,Martin Bidlingmaier et al.
Evelyn Fischer et al.
The Endocrine Society guidelines suggest to screen patients with primary aldosteronism (PA) free of hypertensive medications or alternatively to switch to drugs known to have minimal influence on the aldosterone to renin ratio (ARR). We ret...
Central leptin and ghrelin signalling: comparing and contrasting their mechanisms of action in the brain [0.03%]
中枢瘦素和脑肠肽信号传导：比较与对比其在大脑中的作用机制
Xiaoye Shan,Giles S H Yeo
Xiaoye Shan
In the past two decades, two major discoveries have greatly contributed to our current knowledge on the central control of food intake and body-weight; the discovery of the anorexigenic adipocyte derived hormone leptin in 1994 and the orexi...
Rohit Kohli,Margaret A Stefater,Thomas H Inge
Rohit Kohli
Bariatric surgical procedures have become important therapeutic options for treatment of morbid obesity in both adults and adolescents co-morbidities of obesity such as glucose intolerance, type 2 diabetes (T2DM), metabolic syndrome, steato...
Norman M Kaplan
Norman M Kaplan
This paper provides evidence that primary aldosteronism is likely much less common than is believed by the other authors of this collection. The basis for this contrarian view is simple: there is no way to know the true prevalence of PA bec...
Asterios Karagiannis
Asterios Karagiannis
Primary aldosteronism (PA) is an important cause of secondary hypertension, is being increasingly diagnosed and may account for more than 10% of hypertensive patients, both in primary care and in referral centers. Aldosterone excess is asso...